Surgical Science Sweden Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Surgical Science Sweden has been growing earnings at an average annual rate of 55.5%, while the Medical Equipment industry saw earnings growing at 21.2% annually. Revenues have been growing at an average rate of 47.2% per year. Surgical Science Sweden's return on equity is 4.3%, and it has net margins of 23.6%.
Belangrijke informatie
55.5%
Groei van de winst
51.1%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 6.2% |
| Inkomstengroei | 47.2% |
| Rendement op eigen vermogen | 4.3% |
| Nettomarge | 23.6% |
| Volgende winstupdate | 14 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Surgical Science Sweden AB (publ) Just Missed EPS By 22%: Here's What Analysts Think Will Happen Next
Aug 25
Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Is There Now An Opportunity In Surgical Science Sweden AB (publ) (STO:SUS)?
Nov 29Should You Be Adding Surgical Science Sweden (STO:SUS) To Your Watchlist Today?
Oct 07Is Surgical Science Sweden AB (publ) (STO:SUS) Trading At A 39% Discount?
Aug 17With EPS Growth And More, Surgical Science Sweden (STO:SUS) Makes An Interesting Case
Jun 20A Look At The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
May 17Surgical Science Sweden AB (publ) (STO:SUS) Shares Could Be 49% Below Their Intrinsic Value Estimate
Dec 27Is Now The Time To Put Surgical Science Sweden (STO:SUS) On Your Watchlist?
Dec 06Is Now The Time To Look At Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Sep 08We Ran A Stock Scan For Earnings Growth And Surgical Science Sweden (STO:SUS) Passed With Ease
Aug 23Surgical Science Sweden AB (publ) (STO:SUS) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
May 26Here's Why We Think Surgical Science Sweden (STO:SUS) Is Well Worth Watching
Apr 29An Intrinsic Calculation For Surgical Science Sweden AB (publ) (STO:SUS) Suggests It's 44% Undervalued
Feb 20Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jan 11Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Dec 15Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Sep 16Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jul 05Calculating The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Jun 08Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Mar 23Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Mar 02Is Surgical Science Sweden AB (publ)'s (STO:SUS) Shareholder Ownership Skewed Towards Insiders?
Feb 09
Surgical Science Sweden AB (publ)'s (STO:SUS) Stock Is Going Strong: Have Financials A Role To Play?
Jan 01What Does Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Indicate?
Dec 14Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Nov 26Opbrengsten en kosten
Hoe Surgical Science Sweden geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 838 | 198 | 239 | 181 |
| 31 Mar 24 | 842 | 208 | 233 | 181 |
| 31 Dec 23 | 883 | 234 | 240 | 182 |
| 30 Sep 23 | 906 | 253 | 230 | 182 |
| 30 Jun 23 | 901 | 234 | 228 | 185 |
| 31 Mar 23 | 872 | 221 | 221 | 179 |
| 31 Dec 22 | 803 | 188 | 202 | 173 |
| 30 Sep 22 | 750 | 138 | 200 | 159 |
| 30 Jun 22 | 640 | 124 | 176 | 130 |
| 31 Mar 22 | 489 | 101 | 146 | 97 |
| 31 Dec 21 | 367 | 86 | 117 | 66 |
| 30 Sep 21 | 209 | 30 | 76 | 37 |
| 30 Jun 21 | 138 | 21 | 60 | 26 |
| 31 Mar 21 | 122 | 18 | 53 | 20 |
| 31 Dec 20 | 105 | 16 | 50 | 17 |
| 30 Sep 20 | 104 | 14 | 51 | 18 |
| 30 Jun 20 | 112 | 19 | 54 | 19 |
| 31 Mar 20 | 107 | 17 | 52 | 19 |
| 31 Dec 19 | 102 | 13 | 51 | 17 |
| 30 Sep 19 | 88 | 6 | 49 | 15 |
| 30 Jun 19 | 70 | -5 | 43 | 13 |
| 31 Mar 19 | 68 | -5 | 43 | 13 |
| 31 Dec 18 | 66 | -5 | 39 | 14 |
| 30 Sep 18 | 60 | -3 | 38 | 10 |
| 30 Jun 18 | 57 | -6 | 37 | 7 |
| 31 Mar 18 | 56 | -7 | 34 | 4 |
| 31 Dec 17 | 57 | -3 | 31 | 0 |
| 30 Sep 17 | 65 | 4 | 30 | 0 |
| 30 Jun 17 | 60 | 3 | 27 | 0 |
| 31 Mar 17 | 59 | 4 | 27 | 0 |
| 31 Dec 16 | 58 | 3 | 29 | 0 |
| 31 Dec 15 | 52 | 2 | 24 | 0 |
| 31 Dec 14 | 41 | -3 | 21 | 0 |
Kwaliteitswinsten: SUS has high quality earnings.
Groeiende winstmarge: SUS's current net profit margins (23.6%) are lower than last year (25.9%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: SUS has become profitable over the past 5 years, growing earnings by 55.5% per year.
Versnelling van de groei: SUS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: SUS had negative earnings growth (-15.4%) over the past year, making it difficult to compare to the Medical Equipment industry average (28.2%).
Rendement op eigen vermogen
Hoge ROE: SUS's Return on Equity (4.3%) is considered low.